FDA Lifts Nex-Z Clinical Hold; Intellia's In Vivo CRISPR Story Gains Momentum

What happened

A recent Seeking Alpha article reports that the FDA has lifted the clinical hold on Intellia's Nex-Z Phase 3 trials for ATTR amyloidosis, unlocking a $16.8 billion market opportunity. This follows positive Phase 3 data for Lonvo-Z in HAE, which showed an 87% attack reduction, though the market reacted cautiously due to lingering safety concerns and a competitive landscape. The DeepValue report had previously flagged the hold as a critical watch item and maintained a HOLD rating, noting that a lift with a clear path would likely shift the thesis to BUY. With the hold resolved, Intellia's ATTR program can advance, and the company is positioned to file a BLA for Lonvo-Z in the second half of 2026. Still, investors should weigh the muted commercial outlook for Lonvo-Z given new HAE entrants and the need to monitor hepatic safety data from Nex-Z as trials resume.

Implication

If Nex-Z successfully advances through Phase 3 and Lonvo-Z gains approval, Intellia could capture significant share in two large markets with durable one-time therapies. However, payer skepticism, competition from oral and injectable alternatives in HAE, and the still-unresolved hepatic safety signal in ATTR demand disciplined execution. Investors should watch for enrollment updates, safety data, and partnership developments as key milestones.

Thesis delta

The FDA lift of the Nex-Z clinical hold removes a major overhang, shifting the risk/reward from balanced to positively skewed. This reduces the binary downside scenario and supports an upgrade from HOLD to BUY, contingent on clean safety readouts and competitive positioning for Lonvo-Z. The thesis now hinges on successful Phase 3 execution for both programs rather than regulatory uncertainty.